NCT07147257View on ClinicalTrials.gov

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL

Enrollment

238

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

May 6, 2025

Study Completion Date

May 29, 2025

Conditions

Healthy Participants

Interventions

BIOLOGICAL

CHS-1420

Dose of 40 mg will be subcutaneously administered to participants in

BIOLOGICAL

HUMIRA®

Dose of 40 mg will be subcutaneously administered to participants in

Trial Locations (1)

Unknown

Ethics Committee of Hopeshine-Minsheng Hospital of Xinzheng, Zhengzhou

All Listed Sponsors

lead

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.

INDUSTRY

NCT07147257 - A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions | Biotech Hunter | Biotech Hunter